Somatropin vs Somapacitan: What the Research Compares

Somatropin and somapacitan are both prescription medicines. Somatropin is recombinant human growth hormone, used in growth hormone deficiency and several other approved indications. Somapacitan is a long-acting growth hormone derivative that was developed for administration on a once-weekly schedule and has been studied in adults and in children with growth hormone deficiency. This page summarises what the published literature reports when the two are compared, and it does not rank them, recommend either one, or describe how either is used. A broader background page on the daily product is available in the somatropin overview.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or medicines.

Is There a Direct Head-to-Head Comparison?

Among the papers summarised on this page there is no single named randomized head-to-head trial report comparing somatropin with somapacitan. The closest direct comparisons in this citation set are a network meta-analysis that pooled clinical trials of long-acting growth hormone against daily growth hormone in growth hormone deficiency (PMID 42538635), a continuous glucose monitoring study that examined daily and weekly growth hormone therapy in the same analysis (PMID 41472888), and two switch studies in which adults already receiving somatropin were transitioned to somapacitan and reassessed (PMID 42335808, PMID 41955533). Because the designs differ, the two evidence bases are described side by side below rather than merged into a single verdict.

Network meta-analysis of long-acting versus daily growth hormone

Researchers published a network meta-analysis of clinical trials comparing long-acting growth hormone preparations with daily growth hormone in patients with growth hormone deficiency (PMID 42538635). A network meta-analysis of this kind pools randomized trials that share a common comparator so that products studied in separate trials can be placed on the same statistical framework. The study design means its conclusions were drawn from indirect as well as direct comparisons, which is a recognised limitation whenever individual trials were not run against each other directly (PMID 42538635).

Switch studies in adults

A pilot study examined thyroid hormone levels in adults with growth hormone deficiency after switching from somatropin to somapacitan, with the authors framing thyroid axis measurement as a question that arises when the administration schedule changes (PMID 42335808). A separate report examined metabolic and muscular outcomes in adults with growth hormone deficiency who switched from somatropin to somapacitan (PMID 41955533). Switch designs of this type follow the same participants across two treatments rather than randomising separate groups, so they describe within-person change and were not structured to establish superiority of either medicine (PMID 41955533).

Side-by-Side Summary of the Two Evidence Bases

Class and Mechanism

Somatropin is recombinant human growth hormone with the amino acid sequence of the endogenous hormone. It acts at the growth hormone receptor and raises circulating insulin-like growth factor I, which is the laboratory marker most often followed in growth hormone studies. Somapacitan belongs to the long-acting growth hormone category, a group of molecules modified so that circulating exposure is extended across a weekly interval rather than requiring daily administration. A review of long-acting growth hormone for pediatric growth hormone deficiency described this category and the rationale behind extending the dosing interval (PMID 40144813).

Because exposure is spread differently across the week, pharmacokinetic and pharmacodynamic modelling has been a prominent part of the somapacitan literature. Researchers published a dose-exposure-IGF-I response analysis of once-weekly somapacitan in adults with growth hormone deficiency, linking administered exposure to the IGF-I response that clinicians monitor (PMID 35521713). That kind of analysis exists precisely because weekly administration produces a different exposure shape than daily administration, and interpretation of a single IGF-I measurement depends on where in the week the sample was drawn (PMID 35521713).

Regulatory Status

Both compounds are regulated as prescription medicines. Somatropin products are approved by regulators including the United States Food and Drug Administration for growth hormone deficiency and additional approved indications, and multiple somatropin formulations from different manufacturers are marketed. Somapacitan is approved in the United States under the brand name Sogroya for growth hormone deficiency, with approvals covering adults and children, and it is also authorised in other regions. Prescribing decisions, product selection and monitoring are matters for a licensed prescriber working from the approved labelling in the relevant country.

Pediatric Evidence

In children, a review covering long-acting growth hormone for pediatric growth hormone deficiency summarised the development of weekly agents against the long-standing background of daily therapy (PMID 40144813). A separate study reported that growth response to weekly somapacitan therapy in children with growth hormone deficiency was related to growth hormone thresholds used in growth hormone stimulation testing, meaning the diagnostic cut-off applied at baseline was associated with the growth response observed (PMID 40104568). That finding concerns how patients are selected and classified rather than a direct comparison of one medicine against the other (PMID 40104568).

Glucose Metabolism Across Daily and Weekly Schedules

Growth hormone influences glucose handling, so the question of whether a weekly exposure profile produces a different glycaemic pattern than a daily one has been studied directly. Researchers used continuous glucose monitoring to characterise glucose profiles during daily and weekly growth hormone therapy and reported that the profiles were distinct between the two schedules (PMID 41472888). Continuous glucose monitoring captures variation across the full day rather than at single clinic draws, which is why it was selected for that comparison (PMID 41472888).

A case report described long-acting growth hormone use in a patient with adult growth hormone deficiency coexisting with type 1 diabetes mellitus (PMID 41018171). A single case report describes one patient under one set of circumstances and cannot be generalised to a population, but it illustrates why glucose monitoring appears repeatedly in this literature (PMID 41018171).

Adverse Events and Monitoring Findings: What Studies Report

The verified papers summarised here focus more on laboratory and metabolic parameters than on tolerability tabulations, so the observations below are limited to what those papers examined.

• Thyroid hormone levels. A pilot study examined thyroid hormone levels in adults with growth hormone deficiency after switching from somatropin to somapacitan, treating the thyroid axis as a parameter worth tracking when the administration schedule changes (PMID 42335808).
• Glucose profiles. Researchers reported distinct glucose profiles with daily and weekly growth hormone therapy when continuous glucose monitoring was applied (PMID 41472888).
• Metabolic and muscular parameters. A study assessed metabolic and muscular effects in adults who switched from somatropin to somapacitan (PMID 41955533).
• IGF-I exposure. The dose-exposure-IGF-I analysis in adults characterised how IGF-I responded across the weekly interval, a measurement that underpins laboratory monitoring in this setting (PMID 35521713).
• Coexisting diabetes. A case report documented long-acting growth hormone use in adult growth hormone deficiency coexisting with type 1 diabetes mellitus (PMID 41018171).

Approved product labelling for each medicine carries the full regulator-reviewed safety information, and that labelling, not a summary page, is the reference a prescriber works from.

What the Comparison Does Not Settle

1. Design heterogeneity. The pooled comparison of long-acting against daily growth hormone drew on trials that were not all run against each other directly (PMID 42538635).
2. Small switch cohorts. One of the switch reports was explicitly described by its authors as a pilot study (PMID 42335808).
3. Different populations. Pediatric findings on growth response and stimulation test thresholds (PMID 40104568) do not transfer automatically to adults studied for metabolic and muscular outcomes (PMID 41955533).
4. Monitoring interpretation. Because weekly exposure varies across the interval, IGF-I interpretation depends on sampling, as the dose-exposure analysis illustrated (PMID 35521713).

Nothing on this page identifies a preferred medicine. The literature describes two prescription growth hormone products with overlapping indications, different administration schedules in their study designs, and evidence bases that have only partly been compared against one another.

References

• Long-Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta-Analysis of Clinical Trials (Endocrinology, Diabetes & Metabolism, 2026)
• Effects of switching from somatropin to somapacitan on thyroid hormone levels in adult growth hormone deficiency: A pilot study (Growth Hormone & IGF Research, 2026)
• Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency (The Journal of Clinical Endocrinology and Metabolism, 2026)
• Distinct Glucose Profiles with Daily and Weekly Growth Hormone Therapy Revealed by Continuous Glucose Monitoring (Journal of the Endocrine Society, 2026)
• Long-acting GH Use in Patients With Adult GH Deficiency Coexisting With Type 1 Diabetes Mellitus (JCEM Case Reports, 2025)
• Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency (Journal of the Endocrine Society, 2025)
• Growth Response to Weekly Somapacitan Therapy in Children With GH Deficiency Is Related to GH Thresholds in GH Stimulation Testing (Journal of the Endocrine Society, 2025)
• Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency (European Journal of Endocrinology, 2022)